Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Global license or buyout of pipeline?

<< Previous

Bullboard Posts

Next >>

Comment by lscfaon Dec 17, 2021 10:22am

177 Views

Post# 34240366

RE:Global license or buyout of pipeline?

What about TFC-1394? These boneheads have created confusion just like when they licensed inferior ingredient TFC-849 to Valeant.

Asia
We continue to implement our Asia strategy and are in discussions with a China-based company which has established cosmetic development excellence as discussed in our last news update. An evolving and varied regulatory landscape for new compounds throughout Asia has created challenges. Each country in Asia has enormous commercial potential and we do not want to miss any of these opportunities. As such, we are advancing another compound, TFC-1394, from our patented library of skin lighteners to the same level as TFC-1067. This will occur over the next 12-18 months and ensure that country regulatory testing, if required, can be performed by other companies. We will then be able to launch in every country where a market exists in this $20 Billion USD industry. Our scientists have outlined a development path based on the expertise we have developed which is both efficient and affordable. It will occur in parallel to commercialization of TFC-1067 and not delay current plans. The value of our portfolio, which includes TFC-1067 and TFC-1394, will grow as they advance towards becoming a new industry gold standard as both safe and effective compounds. Having a regional partner is an important component in successful achieving our goals in a timely manner.

Tinyi Trading Company remains on board to be a distribution partner, however, with current discussions ongoing, we wait to see if the new partner in China seeks exclusive distribution. Ultimately, we will decide in the best interests of our company and shareholders.

Vancouver, British Columbia – April 23, 2014 – Sirona Biochem Corp. (TSX-V: SBM.V OTCQX: SRBCF, Frankfurt: ZSB) announces the expansion of its exclusive license with Valeant Pharmaceuticals (“Valeant”) for Sirona’s skin lightening compound TFC-849 to include AMBI and Kinerase. Under the terms of the licensing agreement, Valeant has the exclusive global rights to TFC-849 for use throughout its international portfolio of companies and brands. AMBI and Kinerase, along with Obagi Medical Products (see press release dated January 29, 2014), are part of Valeant’s diverse portfolio focused primarily on dermatology.